Immune responses of a designed HIV-1 DNA vaccine on rhesus monkeys

Chinese Science Bulletin

Volumn 51, Issue 13, 2006, Pages 1571-1577

  Zhang, Lishu ^a   Jin, Ningyi ^a   Song, Yingjin ^b   Sun, Yansong ^a   Wang, Hong ^c   Zhan, Dawei ^a   Ma, Hewen ^d   Shang, Yupu ^a   Jin, Hongtao ^a   Hong, Baoqing ^a   Li, Chang ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b TIANJIN UNIVERSITY   (China)

^c JINAN UNIVERSITY   (China)

^d JILIN UNIVERSITY   (China)

Author keywords

Designed; DNA vaccine; HIV 1; Immune response; Rhesus monkey

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA MULATTA;

EID: 33748948955     PISSN: 10016538     EISSN: 18619541     Source Type: Journal    
DOI: 10.1007/s11434-006-1571-9     Document Type: Article

References (40)

1. State Council AIDS Working Committee Office and UN Theme Group on HIV/AIDS in China. A Joint Assessment of HIV/AIDS Prevention, Treatment and Care in China (2004). 2004: 4-10.
2. Palella F J, Delaney K M, Moorman A C, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. Outpatient Study Investigators. New Engl J Mod, 1998, 338:853-860
3. Mocroft A, Vella S, Benfield T L, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet, 1998, 352: 1725-1730
4. Walmsley S, Bernstein B, King M, et al. Lopinavir: Ritonavir versus nelfinavir for the initial treatment of HIV infection. New Engl J Med, 2002, 346: 2039-2046
5. Daniel M D, Kirchhoff F, Czajak S C, et al. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science, 1992, 258: 1938-1941
6. Cranage M P, Hall G A, Dennis M J, et al. Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology, 1997, 229(1): 143-154
7. Smith S M, Khoroshev M, Marx P A, et al. Constitutively dead, conditionally live HIV-1 genomes. Ex vivo implications for a live virus vaccine. J Biol Chem, 2001, 276(34): 32184-32190
8. Stebbings R, Berry N, Stott J, et al. Vaccination with live attenuated simian immunodeficiency virus for 21 days protects against superinfection. Virology, 2004, 330(1): 249-260
9. Singh D K, Liu Z, Sheffer D, et al. A noninfectious simian/human immunodeficiency virus DNA vaccine that protects macaques against AIDS. J Virol, 2005, 79(6): 3419-3428
10. Peng J M, Tong G Z, Wang Y F, et al. Multi-epitope DNA vaccines against avian influenza in chickens. Chin J Biotech (in Chinese). 2003, 19(5): 623-627
11. Wang X H, Tong D Y, Xu H B, et al. Construction and immunogenecity of a multi-epitope sased SARS-CoV gene vaccine. J Shanghai Med Univ (in Chinese), 2005, 32(2): 130-133
12. Ding J, He F, Lu Y, et al. Induction of multi-epitope-specific antibodies against HIV-1 by multi-epitope-vaccine. Chin Sci Bull, 2001, 46(22): 13-18.
13. Sambrook J, Fritsch E F, Maniatis T. Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1989. 16-68
14. Li Z J, Jin N Y, Jiang W Z, et al. A new type of multiple-epitope DNA vaccine against HIV. Chin J Microbiol Immunol (in Chinese), 2004, 24 (11): 910-913
15. Walker B D, Korber B T. Immune control of HIV: The obstacles of HLA and viral diversity. Nat Immun, 2001, 2: 473-475
16. Korber B, Gaschen B, Yusim K, et al. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull, 2001, 58: 19-42
17. Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science, 2002, 296: 2354-2360
18. Novitsky V, Smith U R, Gilbert P, et al. Human immunodeficiency virus type 1 subtype C molecular phylogeny: Consensus sequence for an AIDS vaccine design? J Virol, 2002, 76(11): 5435-5451
19. Williamson A L, Marais D, Passmore J A, et al. Human papillomavirus (HPV) infection in Southern Africa: Prevalence, immunity, and vaccine prospects. IUBMB Life, 2002, 53(4-5): 253-258
20. Mashishi T, Loubser S, Hide W, et al. Conserved domains of subtype C Nef from South African HIV type 1-infected individuals include cytotoxic T lymphocyte epitope-rich regions. AIDS Res Hum Retroviruses, 2001, 17(17): 1681-1687
21. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol, 1994, 68(9): 6103-6110
22. Koup R A, Safrit J T, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol, 1994, 68(7): 4650-4655
23. Rosenberg E S, Billingsley J M, Caliendo A M, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science, 1997, 278: 1447-1450
24. Ogg G S, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science, 1998, 279:2103-2106
25. + T cells in HIV-infected progressors and long-term nonprogressors. J Immunol, 2000, 165: 1082-1092
26. Chouquet C, Autran B, Gomard E, et al. Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection. AIDS, 2002, 16: 2399-2407
27. Barouch D H, Santra S, Kuroda M J, et al. Reduction of simian-human immunodeficiency virus 89. 6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol, 2001, 75(11): 5151-5158
28. Amara R R, Villinger F, Altman J D, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science, 2001, 292: 69-74
29. Shiver J W, Fu T M, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature, 2002, 415: 331-335
30. Horton H, Vogel T U, Carter D K, et al. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus(SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIV mac239. J Virol, 2002, 76(14): 7187-7202
31. Allen T M, O'Connor D H, Jing P, et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature, 2000, 407: 386-390
32. Barouch D H, Kunstman J, Kuroda M J, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature, 2002, 415: 335-339
33. Vogel T U, Friedrich T C, O'Connor D H, et al. Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: A paradigm for virus evolution and persistence? J Virol, 2002, 76(22): 11623-11636
34. Nacsa J, Stanton J, Kunstman K J, et al. Emergence of cytotoxic T lymphocyte escape mutants following antiretroviral treatment suspension in rhesus macaques infected with SIVmac251. Virology, 2003, 305(1): 210-218
35. Romagnai S. Human Th1 and Th2 subsets: dout no more. Immunol Today, 1991, 12: 256-257
36. Adorini L, Sinigaglia F. Pathogenesis and immunotherapy of autoimmune diseases. Immunol Today, 1997, 18: 209-211
37. Romagnani S. The Th1/Th2 paradigm. Immunol Today, 1997, 18: 263-266
38. Clerici M, Shearer G M. A Th1→Th2 switch is a critical step in the etiology of HIV infection. Immunol Today, 1993, 14:107-111
39. Clerici M, Sarin A, Coffman R L, et al. Type 1/type 2 cytokine modulation of T-cell programed cell death as a model for human immunodeficiency virus pathogenesis. Proc Natl Acad Sci USA, 1994, 91: 11811-11815
40. Clerici M, Lucey D R, Berzofsky J A, et al. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science, 1993, 262: 1721-1724